바이오테크 보도자료
-
- Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs
- Medidata, a Dassault Systèmes company, recently named Rama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veterans, with Chilukuri as the founding president of Medidata Acorn AI and Kondru as executive vice president and chief technology o...
- 2021년 09월 29일
-
- Takeda, dentsu and Finastra Awarded Designation as Best in Enterprise ResilienceTM Leaders as Part of Everbridge’s Global Critical Event Management (CEM) Certification Program
- Everbridge, Inc. (NASDAQ: EVBG) today announced that global industry leaders Takeda Pharmaceutical Company Limited (“Takeda”), dentsu international and Finastra are among the elite multi-national businesses to achieve the prestigious Best in Enter...
- 2021년 09월 28일
-
- VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment o...
- 2021년 09월 28일
-
- SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that ...
- 2021년 09월 28일
-
- IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
- IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021. This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective prod...
- 2021년 09월 24일
-
- Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen health systems and ...
- 2021년 09월 24일
-
- Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
- Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides di...
- 2021년 09월 24일
-
- Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients
- Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase...
- 2021년 09월 24일
-
- Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
- Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed ...
- 2021년 09월 23일
-
- Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy
- Organon (NYSE: OGN), a global women’s health company, is launching a Public Service Announcement (PSA) that aims to raise awareness and ignite a worldwide conversation about the staggering rates of unplanned pregnancy around the world. Worldwide, ...
- 2021년 09월 23일
-
- Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
- Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of an underwritten public offering of 6,670,000 shares of its com...
- 2021년 09월 17일
-
- Philip Morris International Announces Unconditional Offer for Vectura Group PLC
- PMI Global Services Inc. (PMI) (NYSE: PM) today announced that its offer for Vectura Group plc (Vectura) (LSE: VEC) has become unconditional, having received valid acceptances for or acquired 74.77 % of Vectura shares, in excess of the 50% require...
- 2021년 09월 17일
-
- Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of...
- 2021년 09월 17일
전시회
